nach oben

Erschienen in:

18.05.2018 | Original Article

Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer

verfasst von: Tomofumi Miura, Shuichi Mitsunaga, Masafumi Ikeda, Izumi Ohno, Hideaki Takahashi, Hidetaka Suzuki, Ai Irisawa, Takeshi Kuwata, Atsushi Ochiai

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Acyl ghrelin is an orexigenic peptide. Active ghrelin ratio, the ratio of acyl ghrelin to total ghrelin, has an important role in physiological functions and gastrointestinal symptoms. However, low active ghrelin ratio-related characteristics, gastrointestinal symptoms, and chemotherapy-induced gastrointestinal toxicity in patients with advanced pancreatic cancer have not been previously evaluated. The goal of this study was to identify low active ghrelin ratio-related factors in treatment-naïve advanced pancreatic cancer patients.

Methods

Patients with treatment-naïve advanced pancreatic cancer were eligible for inclusion in this study. Active ghrelin ratio and clinical parameters of patients were prospectively recorded. Factors correlated with low active ghrelin ratio and survival were analyzed.

Results

In total, 92 patients were analyzed. Low active ghrelin ratio-related factors were advanced age (P < 0.01), severe appetite loss (P < 0.01), and decreased cholinesterase (P < 0.01). The adverse events of grade 2 or higher anorexia tended to increase in patients with low active ghrelin ratio. However, no differences were found in survival and body composition between low and high active ghrelin ratio groups.

Conclusions

Low active ghrelin ratio was related to lack of appetite and low cholinesterase and tended to be related to anorexia grade 2 or higher in patients with treatment-naïve advanced pancreatic cancer.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660CrossRef

Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, Janssens J, Peeters T (2006) Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 55:327–333CrossRef

Fahim MA, Kataya H, El-Kharrag R, Amer DA, al-Ramadi B, Karam SM (2011) Ghrelin attenuates gastrointestinal epithelial damage induced by doxorubicin World Journal of Gastroenterology: WJG 17: 3836CrossRef

Broglio F, Prodam F, Riganti F, Gottero C, Destefanis S, Granata R, Muccioli G, Abribat T, van der Lely AJ, Ghigo E (2008) The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans. J Endocrinol Investig 31:788–794CrossRef

Ozawa T, Tokunaga J, Arakawa M, Ishikawa A, Takeuchi R, Mezaki N, Miura T, Sakai N, Hokari M, Takeshima A (2013) Abnormal ghrelin secretion contributes to gastrointestinal symptoms in multiple system atrophy patients. J Neurol 260:2073–2077CrossRef

Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M (2005) Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920–2926CrossRef

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. The Lancet Oncol 12:489–495CrossRef

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer The New England journal of medicine 364: 1817–1825CrossRef

Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N (2014) Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer Cancer science 105: 1321–1326

10.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef

11.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Antiemesis. Ver. 2. 2017

12.

Peterson DE, Bensadoun RJ, Roila F (2011) Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 22 Suppl 6: vi78-84CrossRef

13.

Hiura Y, Takiguchi S, Yamamoto K, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M, Doki Y (2012) Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol 17:316–323CrossRef

14.

Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M, Kangawa K, Doki Y (2012) Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 118:4785–4794CrossRef

15.

Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Japanese version of the MD Anderson symptom inventory: a validation study. J Pain Symptom Manag 26:1093–1104CrossRef

16.

Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M (2005) Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18–24CrossRef

17.

Takiguchi S, Adachi S, Yamamoto K, Morii E, Miyata H, Nakajima K, Yamasaki M, Kangawa K, Mori M, Doki Y (2012) Mapping analysis of ghrelin producing cells in the human stomach associated with chronic gastritis and early cancers. Dig Dis Sci 57:1238–1246CrossRef

18.

Taal BG, Boot H, van Heerde P, de Jong D, Hart AA, Burgers JM (1996) Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut 39:556–561CrossRef

19.

Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, Cunningham GR (2006) Hypogonadism in male patients with cancer Cancer 106: 2583–2591CrossRef

20.

Malendowicz W, Ziolkowska A, Szyszka M, Kwias Z (2009) Elevated blood active ghrelin and unaltered total ghrelin and obestatin concentrations in prostate carcinoma. Urol Int 83:471–475CrossRef

21.

Markowska A, Ziółkowska A, Jaszczyńska-Nowinka K, Madry R, Malendowicz L (2009) Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers. Eur J Gynaecol Oncol 30:518–522PubMed

22.

Koyama KI, Yasuhara D, Nakahara T, Harada T, Uehara M, Ushikai M, Asakawa A, Inui A (2010) Changes in acyl ghrelin, des-acyl ghrelin, and ratio of acyl ghrelin to total ghrelin with short-term refeeding in female inpatients with restricting-type anorexia nervosa. Hormone and metabolic research = Hormon- und Stoffwechselforschung = hormones et metabolisme 42:595–598CrossRef

23.

Broglio F, Gianotti L, Destefanis S, Fassino S, Abbate Daga G, Mondelli V, Lanfranco F, Gottero C, Gauna C, Hofland L, Van der Lely AJ, Ghigo E (2004) The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state. Clin Endocrinol 60:592–599CrossRef

24.

Miljic D, Pekic S, Djurovic M, Doknic M, Milic N, Casanueva FF, Ghatei M, Popovic V (2006) Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. J Clin Endocrinol Metab 91:1491–1495CrossRef

25.

Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519–531CrossRef

26.

Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N, Ochiai A (2008) Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion. Pancreas 36:241–248CrossRef

27.

Han X, Wu Z, Di J, Pan Y, Zhang H, Du Y, Cheng Z, Jin Z, Wang Z, Zheng Q (2011) CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. Biomed Pharmacother 65:547–554CrossRef

28.

Soares PM, Lopes LO, Mota JMS, Belarmino-Filho JN, Ribeiro RA, de Souza MHL (2011) Methotrexate-induced intestinal mucositis delays gastric emptying and gastrointestinal transit of liquids in awake rats. Arquivos de gastroenterologia 48:80–85CrossRef

29.

Russo F, Linsalata M, Clemente C, D'Attoma B, Orlando A, Campanella G, Giotta F, Riezzo G (2013) The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer 13:56CrossRef

30.

Sibilia V, Rindi G, Pagani F, Rapetti D, Locatelli V, Torsello A, Campanini N, Deghenghi R, Netti C (2003) Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology 144:353–359CrossRef

31.

Warzecha Z, Ceranowicz D, Dembiński A, Ceranowicz P, Cieszkowski J, Kuwahara A, Kato I, Dembiński M, Konturek PC (2012) Ghrelin accelerates the healing of cysteamine-induced duodenal ulcers in rats Medical science monitor: international medical journal of experimental and clinical research 18: BR181

32.

Konturek P, Brzozowski T, Engel M, Burnat G, Gaca P, Konturek S (2009) Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves Acta physiologica Polonica 60: 41

33.

Waseem T, Duxbury M, Ito H, Rocha F, Lautz D, Whang E, Ashley S, Robinson M (2004) Ghrelin ameliorates TNF-a induced anti-proliferative and pro-apoptotic effects and promotes intestinal epithelial restitution Journal of the American College of Surgeons 199: 16CrossRef

34.

Nelson K, Walsh D, Sheehan F (2002) Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 10:455–461CrossRef

35.

Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K (2000) Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 276:905–908CrossRef

36.

Dornonville de la Cour C, Lindstrom E, Norlen P, Hakanson R (2004) Ghrelin stimulates gastric emptying but is without effect on acid secretion and gastric endocrine cells. Regul Pept 120:23–32CrossRef

37.

Edholm T, Levin F, Hellström PM, Schmidt PT (2004) Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regul Pept 121:25–30CrossRef

Titel: Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer
verfasst von: Tomofumi Miura
Shuichi Mitsunaga
Masafumi Ikeda
Izumi Ohno
Hideaki Takahashi
Hidetaka Suzuki
Ai Irisawa
Takeshi Kuwata
Atsushi Ochiai
Publikationsdatum: 18.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4248-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2018

Metastatic breast cancer patients’ expectations and priorities for symptom improvement

Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy

Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study

Factors associated with discharge disposition on an acute palliative care unit

Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia

Does implementation matter if comprehension is lacking? A qualitative investigation into perceptions of advance care planning in people with cancer

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie